Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer immunology research

• Publication date

  2015-03-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-14-0188PMID 25769300PMCID PMC4681575
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

  2014cited by this paper
• Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

  2014cited by this paper
• Human Papillomavirus (HPV) and Overall Survival (OS) After Progression of Oropharyngeal Squamous Cell Carcinoma (OPSCC)

  2014cited by this paper
• Correlation of Fc Gamma Receptor (FcγR) IIa and IIIa Polymorphisms With Clinical Outcome in Patients Treated With Cetuximab-Based Chemoradiation in the RTOG 0522 Trial

  2014cited by this paper
• Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma

  2014cited by this paper
• Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

  2013cited by this paper
• Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab

  2011cited by this paper
• Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers

  2010cited by this paper
• Rituximab: mechanism of action.

  2010cited by this paper
• Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

  2009cited by this paper
• Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia

  2009cited by this paper
• Individual patient data analysis to assess modifications to the RECIST criteria.

  2009cited by this paper
• Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

  2009cited by this paper
• FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck

  2009cited by this paper
• Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

  2008cited by this paper
• Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies.

  2008cited by this paper
• FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.

  2007influential reference
• FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

  2007cited by this paper
• A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.

  2007cited by this paper
• FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab

  2007cited by this paper
• Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

  2006cited by this paper
• Long-Term Preservation of Antibody-Dependent Cellular Cytotoxicity (ADCC) of Natural Killer Cells Amplified In Vitro From the Peripheral Blood of Breast Cancer Patients After Chemotherapy

  2006cited by this paper
• Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

  2005cited by this paper
• Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies

  2005cited by this paper
• Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.

  2004cited by this paper
• Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.

  2004cited by this paper
• Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia.

  2004cited by this paper
• FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

  2004cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002cited by this paper
• Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.

  1997cited by this paper
• FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

  1997cited by this paper

• Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial.

  2025cites this paper
• Immunotherapeutic strategies in head and neck cancer: challenges and opportunities

  2025cites this paper
• Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy

  2024cites this paper
• Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study

  2024cites this paper
• Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors

  2024cites this paper
• The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma

  2024cites this paper
• A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

  2023cites this paper
• Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity

  2023cites this paper
• Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer

  2023cites this paper
• Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients.

  2023cites this paper
• Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma

  2023cites this paper
• Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies

  2022cites this paper
• The prognostic impact of the immune signature in head and neck squamous cell carcinoma

  2022cites this paper
• Natural Killer cells and monoclonal antibodies: two partners for successful antibody dependent cytotoxicity against tumor cells.

  2021cites this paper
• Challenges for NK cell-based therapies: What can we learn from lymph nodes?

  2021cites this paper
• Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.

  2021cites this paper
• Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway

  2021cites this paper
• The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies

  2021cites this paper
• NK Cells in Immunotherapy: How Important Are They?

  2021cites this paper
• Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?

  2020cites this paper
• Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status

  2020cites this paper
• Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity

  2019cites this paper
• Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy

  2019cites this paper
• Effect of Fc Receptor Genetic Diversity on HIV-1 Disease Pathogenesis

  2019cites this paper
• Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells

  2018cites this paper
• Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy

  2018cites this paper
• The polymorphic DNA marker rs 849142 predicts skin toxicity in anti-EGFR treatment of metastatic colorectal cancer

  2018cites this paper
• Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies

  2018cites this paper
• In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

  2018cites this paper
• Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy

  2018cites this paper
• The Role of Targeted Therapy in the Management of Sinonasal Malignancies.

  2017cites this paper
• Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  2017cites this paper
• Transfection of FcγRIIIa (CD16) Alone Can Be Sufficient To Enable Human αβTCR T Lymphocytes To Mediate Antibody-Dependent Cellular Cytotoxicity

  2017cites this paper
• Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy

  2017cites this paper
• The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab

  2017cites this paper
• Natural killer cell-mediated immunosurveillance of human cancer.

  2017cites this paper
• FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma

  2016cites this paper
• Effet de la mutation KRAS LCS6 variant sur la Sensibilité au Cetuximab en première ligne de chimiothérapie palliative dans les carcinomes épidermoïdes des VADS

  2016cites this paper
• Characterization of Therapeutic Proteins

  2016cites this paper
• Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy

  2016cites this paper
• Immunotherapy for Head and Neck Squamous Cell Carcinoma.

  2015cites this paper
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

  2015cites this paper
• PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging

  2015cites this paper
• Positive and Negative Impact of Immune Cells on Disease Outcome in Cancer Patients Treated with Chemotherapy Cells Markers Cancer Type

  2015cites this paper